211 related articles for article (PubMed ID: 34161092)
1. Machine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics.
Bifarin OO; Gaul DA; Sah S; Arnold RS; Ogan K; Master VA; Roberts DL; Bergquist SH; Petros JA; Fernández FM; Edison AS
J Proteome Res; 2021 Jul; 20(7):3629-3641. PubMed ID: 34161092
[TBL] [Abstract][Full Text] [Related]
2. Urine-Based Metabolomics and Machine Learning Reveals Metabolites Associated with Renal Cell Carcinoma Stage.
Bifarin OO; Gaul DA; Sah S; Arnold RS; Ogan K; Master VA; Roberts DL; Bergquist SH; Petros JA; Edison AS; Fernández FM
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944874
[TBL] [Abstract][Full Text] [Related]
3. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
4. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
[TBL] [Abstract][Full Text] [Related]
5. Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH
Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263
[TBL] [Abstract][Full Text] [Related]
6. Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Solmoirago MJ; Sánchez-González JV; Vera-Donoso CD; Martínez-Sarmiento M; España F; Navarro S; Medina P
J Proteomics; 2020 Apr; 218():103723. PubMed ID: 32126320
[TBL] [Abstract][Full Text] [Related]
7. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
[TBL] [Abstract][Full Text] [Related]
8. Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC.
Liu X; Zhang M; Liu X; Sun H; Guo Z; Tang X; Wang Z; Li J; Li H; Sun W; Zhang Y
Front Oncol; 2019; 9():663. PubMed ID: 31380290
[TBL] [Abstract][Full Text] [Related]
9. Automated Machine Learning and Explainable AI (AutoML-XAI) for Metabolomics: Improving Cancer Diagnostics.
Bifarin OO; Fernández FM
J Am Soc Mass Spectrom; 2024 Jun; 35(6):1089-1100. PubMed ID: 38690775
[TBL] [Abstract][Full Text] [Related]
10. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
Gupta A; Nath K; Bansal N; Kumar M
Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
[No Abstract] [Full Text] [Related]
11. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
12. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.
Yilmaz A; Ustun I; Ugur Z; Akyol S; Hu WT; Fiandaca MS; Mapstone M; Federoff H; Maddens M; Graham SF
J Alzheimers Dis; 2020; 78(4):1381-1392. PubMed ID: 33164929
[TBL] [Abstract][Full Text] [Related]
13. Textural differences between renal cell carcinoma subtypes: Machine learning-based quantitative computed tomography texture analysis with independent external validation.
Kocak B; Yardimci AH; Bektas CT; Turkcanoglu MH; Erdim C; Yucetas U; Koca SB; Kilickesmez O
Eur J Radiol; 2018 Oct; 107():149-157. PubMed ID: 30292260
[TBL] [Abstract][Full Text] [Related]
14. Molecular signature of renal cell carcinoma by means of a multiplatform metabolomics analysis.
Kordalewska M; Wawrzyniak R; Jacyna J; Godzień J; López Gonzálves Á; Raczak-Gutknecht J; Markuszewski M; Gutknecht P; Matuszewski M; Siebert J; Barbas C; Markuszewski MJ
Biochem Biophys Rep; 2022 Sep; 31():101318. PubMed ID: 35967759
[TBL] [Abstract][Full Text] [Related]
15. Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.
Zheng H; Ji J; Zhao L; Chen M; Shi A; Pan L; Huang Y; Zhang H; Dong B; Gao H
Oncotarget; 2016 Sep; 7(37):59189-59198. PubMed ID: 27463020
[TBL] [Abstract][Full Text] [Related]
16. LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes.
Jing L; Guigonis JM; Borchiellini D; Durand M; Pourcher T; Ambrosetti D
Sci Rep; 2019 Oct; 9(1):15635. PubMed ID: 31666664
[TBL] [Abstract][Full Text] [Related]
17. Label-Free SERS of Urine Components: A Powerful Tool for Discriminating Renal Cell Carcinoma through Multivariate Analysis and Machine Learning Techniques.
Buhas BA; Toma V; Beauval JB; Andras I; Couți R; Muntean LA; Coman RT; Maghiar TA; Știufiuc RI; Lucaciu CM; Crisan N
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612705
[TBL] [Abstract][Full Text] [Related]
18. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.
Monteiro MS; Barros AS; Pinto J; Carvalho M; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Guedes de Pinho P
Sci Rep; 2016 Nov; 6():37275. PubMed ID: 27857216
[TBL] [Abstract][Full Text] [Related]
19. Machine learning-based quantitative texture analysis of CT images of small renal masses: Differentiation of angiomyolipoma without visible fat from renal cell carcinoma.
Feng Z; Rong P; Cao P; Zhou Q; Zhu W; Yan Z; Liu Q; Wang W
Eur Radiol; 2018 Apr; 28(4):1625-1633. PubMed ID: 29134348
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
